Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Regeneron (REGN)

Tipranks - Tipranks - Fri Apr 24, 10:02AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Regeneron (REGN) with bullish sentiments.

Claim 30% Off TipRanks

Argenx Se (ARGX)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Argenx Se, with a price target of $1000.00. The company’s shares closed last Thursday at $799.71.

According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 19.2% and a 50.8% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $1038.75 average price target, which is a 30.3% upside from current levels. In a report issued on April 14, Bank of America Securities also maintained a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Regeneron (REGN)

In a report released today, Carter Gould from Cantor Fitzgerald maintained a Buy rating on Regeneron, with a price target of $800.00. The company’s shares closed last Thursday at $760.42.

According to TipRanks.com, Gould is a 4-star analyst with an average return of 5.3% and a 50.6% success rate. Gould covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Merck & Company. ;'>

Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $877.32, implying a 16.8% upside from current levels. In a report issued on April 8, Bernstein also maintained a Buy rating on the stock with a $921.00 price target.

Read More on ARGX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).